Oral Anticoagulation Use in Individuals With Atrial Fibrillation and Chronic Kidney Disease: A Review

Area of Science:

• Nephrology
• Cardiology
• Pharmacology

Background:

• Atrial fibrillation (AF) is common in chronic kidney disease (CKD) patients.
• AF in CKD increases stroke risk, particularly with declining kidney function.
• Oral anticoagulation is standard for stroke prevention in general and moderate CKD populations.

Purpose of the Study:

• To review the current literature on oral anticoagulation for stroke prevention in AF patients with CKD.
• To highlight evidence gaps in severe CKD and dialysis populations.
• To discuss strategies for overcoming these evidence deficiencies.

Main Methods:

• Literature review of studies on oral anticoagulation in AF and CKD.
• Analysis of evidence for direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs).
• Examination of pharmacokinetic and safety profiles in different CKD stages.

Main Results:

• DOACs are increasingly preferred over VKAs for AF patients across all CKD stages.
• Evidence for anticoagulation in severe CKD and dialysis patients is limited due to trial exclusions.
• DOACs offer advantages like fewer drug-drug interactions and predictable efficacy.

Conclusions:

• Oral anticoagulation is crucial for managing AF in CKD patients.
• Further research is needed to clarify optimal anticoagulation strategies in severe CKD and dialysis.
• DOACs represent a favorable option for anticoagulation in CKD patients with AF.